Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cetirizine Hydrochloride

FDA-approved product (tablet, oral), marketed as Cetirizine Hydrochloride, Cetirizine Hydrochloride Allergy, Cetirizine Hydrochloride Hives and 11 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cetirizine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic disease
  • Allergic rhinitis
  • Eye allergy
  • Nasal congestion
  • Pruritus
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Piperazine derivatives; Other antiallergics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cetirizine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cetirizine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.

    NCT03296358 · start 2017-10-01

    Registered record
    Registry ID
    NCT03296358
    Conditions
    Urticaria; Allergy
    Interventions
    IV Dexamethasone; Oral prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-10-01
    Completion
    2019-10-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrticaria; Allergy
    InterventionIV Dexamethasone; Oral prednisolone
    PhaseNot applicable
    Registry statusCompleted

  • Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction

    NCT03167216 · start 2017-08-01

    Registered record
    Registry ID
    NCT03167216
    Conditions
    Chronic Prostatitis With Chronic Pelvic Pain Syndrome
    Interventions
    Cromolyn Sodium; Cetirizine Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-08-01
    Completion
    2022-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Prostatitis With Chronic Pelvic Pain Syndrome
    InterventionCromolyn Sodium; Cetirizine Hydrochloride
    PhaseEarly phase 1
    Registry statusCompleted

  • Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

    NCT02935699 · start 2017-03-01

    Registered record
    Registry ID
    NCT02935699
    Conditions
    Acute Urticaria
    Interventions
    Test Drug (JDP-205); Active Control (Diphenhydramine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-01
    Completion
    2018-04-30
    Enrolment
    262

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Urticaria
    InterventionTest Drug (JDP-205); Active Control (Diphenhydramine)
    PhasePhase 3
    Registry statusCompleted

  • High Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria

    NCT02873364 · start 2016-08

    Registered record
    Registry ID
    NCT02873364
    Conditions
    Urticaria
    Interventions
    Vitamin D3 (High dose); Vitamin D3 (Low dose)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2017-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrticaria
    InterventionVitamin D3 (High dose); Vitamin D3 (Low dose)
    PhasePhase 3
    Registry statusUnknown

  • Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

    NCT02738008 · start 2016-03

    Registered record
    Registry ID
    NCT02738008
    Conditions
    Hepatitis B
    Interventions
    ARC-520 Injection; entecavir; tenofovir; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-03
    Completion
    2016-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionARC-520 Injection; entecavir; tenofovir; antihistamine
    PhasePhase 2
    Registry statusTerminated

  • Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

    NCT02613910 · start 2015-12-23

    Registered record
    Registry ID
    NCT02613910
    Conditions
    Pemphigus
    Interventions
    Ofatumumab; Acetaminophen/paracetamol; Antihistamine (cetirizine or equivalent); Prednisone/Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-12-23
    Completion
    2016-03-23
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPemphigus
    InterventionOfatumumab; Acetaminophen/paracetamol; Antihistamine (cetirizine or equivalent); Prednisone/Prednisolone
    PhasePhase 3
    Registry statusTerminated

  • Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

    NCT02577029 · start 2015-12

    Registered record
    Registry ID
    NCT02577029
    Conditions
    Hepatitis B; Hepatitis D
    Interventions
    ARC-520; entecavir; pegylated interferon alpha 2a; tenofovir disoproxil; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-12
    Completion
    2016-12
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; Hepatitis D
    InterventionARC-520; entecavir; pegylated interferon alpha 2a; tenofovir disoproxil +1 more
    PhasePhase 2
    Registry statusTerminated

  • Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.

    NCT03047278 · start 2015-11-01

    Registered record
    Registry ID
    NCT03047278
    Conditions
    Neuropathic Pain; Type 2 Diabetes Mellitus; Diabetic Neuropathy, Painful
    Interventions
    Serial Blood Samples; Serial Urine Samples; Gabapentin 300 mg; Cetirizine Hydrochloride 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-11-01
    Completion
    2019-07-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuropathic Pain; Type 2 Diabetes Mellitus; Diabetic Neuropathy, Painful
    InterventionSerial Blood Samples; Serial Urine Samples; Gabapentin 300 mg; Cetirizine Hydrochloride 10 mg
    PhasePhase 4
    Registry statusCompleted

  • A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

    NCT02604199 · start 2015-09

    Registered record
    Registry ID
    NCT02604199
    Conditions
    Hepatitis B
    Interventions
    ARC-520 Injection; placebo; entecavir; tenofovir; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2017-01
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionARC-520 Injection; placebo; entecavir; tenofovir +1 more
    PhasePhase 2
    Registry statusTerminated

  • Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome

    NCT02394106 · start 2015-07

    Registered record
    Registry ID
    NCT02394106
    Conditions
    Nephrotic Syndrome
    Interventions
    Ofatumumab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-07
    Completion
    2019-06
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNephrotic Syndrome
    InterventionOfatumumab; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Neuromyelitis Optica (NMO) & Cetirizine

    NCT02865018 · start 2014-04

    Registered record
    Registry ID
    NCT02865018
    Conditions
    Neuromyelitis Optica
    Interventions
    cetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromyelitis Optica
    Interventioncetirizine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

    NCT02023164 · start 2013-07

    Registered record
    Registry ID
    NCT02023164
    Conditions
    Acute Urticaria
    Interventions
    JDP-205 Injection; Diphenhydramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Urticaria
    InterventionJDP-205 Injection; Diphenhydramine
    PhasePhase 3
    Registry statusCompleted

  • Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis

    NCT01651871 · start 2012-07

    Registered record
    Registry ID
    NCT01651871
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    S-555739 Dose 1; S-555739 Dose 2; Cetirizine HCl Dose 1; S-555739 placebo; Cetirizine HCl placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-05
    Enrolment
    779

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionS-555739 Dose 1; S-555739 Dose 2; Cetirizine HCl Dose 1; S-555739 placebo +1 more
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic Study of Levocetirizine Oral Solution

    NCT01622283 · start 2012-05-02

    Registered record
    Registry ID
    NCT01622283
    Conditions
    Rhinitis, Allergic, Perennial and Seasonal
    Interventions
    Levocetirizine; Cetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-05-02
    Completion
    2012-06-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial and Seasonal
    InterventionLevocetirizine; Cetirizine
    PhasePhase 1
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

    NCT01484119 · start 2011-12

    Registered record
    Registry ID
    NCT01484119
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    ACT-129968; Placebo; Cetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2012-03
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionACT-129968; Placebo; Cetirizine
    PhasePhase 3
    Registry statusCompleted